Ccr6 Is Dispensable for the Development of Skin Lesions Induced by Imiquimod despite its Effect on Epidermal Homing of IL-22–Producing Cells

Journal of Investigative Dermatology

Volumn 137, Issue 5, 2017, Pages 1094-1103

  Cochez, Perrine M ^a,b   Michiels, Camille ^a,b   Hendrickx, Emilie ^a,b   Dauguet, Nicolas ^b   Warnier, Guy ^a   Renauld, Jean Christophe ^a,b   Dumoutier, Laure ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR6; EPIDERMIN; IMIQUIMOD; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; RAG1 PROTEIN; AMINOQUINOLINE DERIVATIVE; BETA GALACTOSIDASE; CCR6 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; RAG-1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HOMING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMIS; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN DEFECT; T LYMPHOCYTE SUBPOPULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EPIDERMIS; GENE TARGETING; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY;

AMINOQUINOLINES; ANIMALS; BETA-GALACTOSIDASE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EPIDERMIS; GENE KNOCK-IN TECHNIQUES; HOMEODOMAIN PROTEINS; INTERLEUKINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PSORIASIS; RECEPTORS, CCR6; T-LYMPHOCYTE SUBSETS;

EID: 85017532012     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.12.023     Document Type: Article

References (35)

1. Baba, M., Imai, T., Nishimura, M., Kakizaki, M., Takagi, S., Hieshima, K., et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 272 (1997), 14893–14898.
2. Barth, T., Schmidt, D., Botteron, C., Nguyen, T.T., Ritter, U., Mannel, D.N., et al. An early reduction in Treg cells correlates with enhanced local inflammation in cutaneous leishmaniasis in CCR6-deficient mice. PLoS One, 7(9), 2012, e44499.
3. Boniface, K., Bernard, F.X., Garcia, M., Gurney, A.L., Lecron, J.C., Morel, F., IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174 (2005), 3695–3702.
4. Boniface, K., Guignouard, E., Pedretti, N., Garcia, M., Delwail, A., Bernard, F.X., et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 150 (2007), 407–415.
5. Campa, M., Mansouri, B., Warren, R., Menter, A., A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb) 6 (2016), 1–12.
6. Chan, L.C., Chaili, S., Filler, S.G., Barr, K., Wang, H., Kupferwasser, D., et al. Nonredundant roles of interleukin-17A (IL-17A) and IL-22 in murine host defense against cutaneous and hematogenous infection due to methicillin-resistant Staphylococcus aureus. Infect Immun 83 (2015), 4427–4437.
7. Cochez, P.M., Michiels, C., Hendrickx, E., Van Belle, A.B., Lemaire, M.M., Dauguet, N., et al. AhR modulates the IL-22 producing cell proliferation/recruitment in imiquimod-induced psoriasis mouse model. Eur J Immunol 46 (2016), 1449–1459.
8. Cook, D.N., Prosser, D.M., Forster, R., Zhang, J., Kuklin, N.A., Abbondanzo, S.J., et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 12 (2000), 495–503.
9. Grine, L., Steeland, S., Van Ryckeghem, S., Ballegeer, M., Lienenklaus, S., Weiss, S., et al. Topical imiquimod yields systemic effects due to unintended oral uptake. Sci Rep, 6, 2016, 20134.
10. Hedrick, M.N., Lonsdorf, A.S., Hwang, S.T., Farber, J.M., CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 14 (2010), 911–922.
11. Hedrick, M.N., Lonsdorf, A.S., Shirakawa, A.K., Richard Lee, C.C., Liao, F., Singh, S.P., et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 119 (2009), 2317–2329.
12. Homey, B., Dieu-Nosjean, M.C., Wiesenborn, A., Massacrier, C., Pin, J.J., Oldham, E., et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164 (2000), 6621–6632.
13. Kadow, S., Jux, B., Zahner, S.P., Wingerath, B., Chmill, S., Clausen, B.E., et al. Aryl hydrocarbon receptor is critical for homeostasis of invariant gammadelta T cells in the murine epidermis. J Immunol 187 (2011), 3104–3110.
14. Kagami, S., Rizzo, H.L., Kurtz, S.E., Miller, L.S., Blauvelt, A., IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 185 (2010), 5453–5462.
15. Kleinewietfeld, M., Puentes, F., Borsellino, G., Battistini, L., Rotzschke, O., Falk, K., CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 105 (2005), 2877–2886.
16. Kunz, S., Wolk, K., Witte, E., Witte, K., Doecke, W.D., Volk, H.D., et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 15 (2006), 991–1004.
17. Mabuchi, T., Singh, T.P., Takekoshi, T., Jia, G.F., Wu, X., Kao, M.C., et al. CCR6 is required for epidermal trafficking of gammadelta-T cells in an IL-23-induced model of psoriasiform dermatitis. J Invest Dermatol 133 (2013), 164–171.
18. Mabuchi, T., Takekoshi, T., Hwang, S.T., Epidermal CCR6+ gammadelta T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol 187 (2011), 5026–5031.
19. McGee, H.M., Schmidt, B.A., Booth, C.J., Yancopoulos, G.D., Valenzuela, D.M., Murphy, A.J., et al. IL-22 promotes fibroblast-mediated wound repair in the skin. J Invest Dermatol 133 (2013), 1321–1329.
20. Mombaerts, P., Iacomini, J., Johnson, R.S., Herrup, K., Tonegawa, S., Papaioannou, V.E., RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68 (1992), 869–877.
21. Niyonsaba, F., Iwabuchi, K., Matsuda, H., Ogawa, H., Nagaoka, I., Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 14 (2002), 421–426.
22. Pantelyushin, S., Haak, S., Ingold, B., Kulig, P., Heppner, F.L., Navarini, A.A., et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice. J Clin Invest 122 (2012), 2252–2256.
23. Paradis, T.J., Cole, S.H., Nelson, R.T., Gladue, R.P., Essential role of CCR6 in directing activated T cells to the skin during contact hypersensitivity. J Invest Dermatol 128 (2008), 628–633.
24. Sa, S.M., Valdez, P.A., Wu, J., Jung, K., Zhong, F., Hall, L., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178 (2007), 2229–2240.
25. Salgado, C.G., Nakamura, K., Sugaya, M., Tada, Y., Asahina, A., Koyama, Y., et al. Functional CD40 ligand is expressed on epidermal Langerhans cells. J Leukoc Biol 66 (1999), 281–285.
26. Sasaki, J.R., Zhang, Q., Schwacha, M.G., Burn induces a Th-17 inflammatory response at the injury site. Burns 37 (2011), 646–651.
27. Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Schafer, M., Coyle, A.J., et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 122 (2012), 3965–3976.
28. Tubo, N.J., McLachlan, J.B., Campbell, J.J., Chemokine receptor requirements for epidermal T-cell trafficking. Am J Pathol 178 (2011), 2496–2503.
29. Van Belle, A.B., de Heusch, M., Lemaire, M.M., Hendrickx, E., Warnier, G., Dunussi-Joannopoulos, K., et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 188 (2012), 462–469.
30. van der Fits, L., Mourits, S., Voerman, J.S., Kant, M., Boon, L., Laman, J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182 (2009), 5836–5845.
31. Varona, R., Villares, R., Carramolino, L., Goya, I., Zaballos, A., Gutierrez, J., et al. CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. J Clin Invest 107 (2001), R37–R45.
32. Wolk, K., Haugen, H.S., Xu, W., Witte, E., Waggie, K., Anderson, M., et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 87 (2009), 523–536.
33. Wolk, K., Witte, E., Wallace, E., Docke, W.D., Kunz, S., Asadullah, K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36 (2006), 1309–1323.
34. Yamazaki, T., Yang, X.O., Chung, Y., Fukunaga, A., Nurieva, R., Pappu, B., et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 181 (2008), 8391–8401.
35. Zheng, Y., Danilenko, D.M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:7128 (2007), 648–651.